Evaluation of the role of erythropoietin and methotrexate in multiple sclerosis | Zendy

Sandipan Dasgupta | Zendy; Bhaskar Mazumder | Zendy; Y Roja Ramani | Zendy; SubhraPrakash Bhattacharyya | Zendy; MukeshK Das | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Evaluation of the role of erythropoietin and methotrexate in multiple sclerosis

Author(s) -

Sandipan Dasgupta,

Bhaskar Mazumder,

Y Roja Ramani,

SubhraPrakash Bhattacharyya,

MukeshK Das

Publication year - 2011

Publication title -

indian journal of pharmacology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.286

H-Index - 59

eISSN - 1998-3751

pISSN - 0253-7613

DOI - 10.4103/0253-7613.84955

Subject(s) - medicine , methotrexate , erythropoietin , multiple sclerosis , rheumatoid arthritis , immunology , encephalomyelitis , experimental autoimmune encephalomyelitis

Erythropoietin, originally recognized for its role in erythropoiesis, has been shown to improve neurological outcome after stroke. Low-dose methotrexate is effective against certain inflammatory diseases, such as severe psoriasis and rheumatoid arthritis as well as Crohn's disease. Immunosuppressive effect of methotrexate also reduces the proportion of patients with chronic progressive multiple sclerosis with modest clinical benefits. Combination of erythropoietin and methotrexate can target neuroinflammation along with immunosupression.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research